MedTrace Logo

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

NCT04967625 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-07-28

No results posted yet for this study

Summary

This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the efficacy and safety.

23 patients are expected to be enrolled in this study.

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

Sintilimab

A humanized anti-PD-1 monoclonal antibody

DRUG

Anlotinib hydrochloride

A tyrosine kinase inhibitor selectively targeting VEGFR-2

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Guangyuan Lou · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2022-12-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04967625 on ClinicalTrials.gov